SI-BONE, Inc. (NASDAQ:SIBN) CFO Sells $30,483.47 in Stock

SI-BONE, Inc. (NASDAQ:SIBN) CFO Anshul Maheshwari sold 1,733 shares of the firm’s stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $17.59, for a total transaction of $30,483.47. Following the transaction, the chief financial officer now directly owns 148,738 shares in the company, valued at $2,616,301.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Anshul Maheshwari also recently made the following trade(s):

• On Monday, October 2nd, Anshul Maheshwari sold 1,244 shares of SI-BONE stock. The stock was sold at an average price of $21.15, for a total transaction of $26,310.60.

SI-BONE Trading Up 2.9 %

Shares of NASDAQ:SIBN traded up $0.50 during mid-day trading on Monday, hitting $18.04. The company had a trading volume of 230,933 shares, compared to its average volume of 355,422. The firm has a fifty day moving average price of $18.93 and a 200 day moving average price of $22.72. The company has a market capitalization of $730.64 million, a PE ratio of -15.16 and a beta of 0.99. The company has a debt-to-equity ratio of 0.21, a current ratio of 10.89 and a quick ratio of 9.74. SI-BONE, Inc. has a one year low of $11.14 and a one year high of $29.51.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on SIBN shares. Morgan Stanley reduced their price objective on shares of SI-BONE from $30.00 to $25.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 7th. Cantor Fitzgerald reduced their price objective on shares of SI-BONE from $30.00 to $25.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 7th. Truist Financial reduced their price objective on shares of SI-BONE from $33.00 to $31.00 and set a “buy” rating on the stock in a research note on Tuesday, August 8th. Finally, Needham & Company LLC reduced their price objective on shares of SI-BONE from $32.00 to $25.00 and set a “buy” rating on the stock in a research note on Tuesday, November 7th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, SI-BONE has an average rating of “Buy” and a consensus target price of $27.17.

Institutional Trading of SI-BONE

Several hedge funds have recently modified their holdings of SIBN. Divisadero Street Capital Management LP increased its stake in shares of SI-BONE by 173.2% in the 2nd quarter. Divisadero Street Capital Management LP now owns 910,000 shares of the company’s stock valued at $24,552,000 after acquiring an additional 576,942 shares in the last quarter. Marshall Wace LLP bought a new stake in SI-BONE during the 2nd quarter valued at $15,254,000. Silvercrest Asset Management Group LLC increased its stake in SI-BONE by 154.6% during the 1st quarter. Silvercrest Asset Management Group LLC now owns 900,969 shares of the company’s stock valued at $17,722,000 after purchasing an additional 547,141 shares in the last quarter. First Light Asset Management LLC increased its stake in SI-BONE by 50.6% during the 1st quarter. First Light Asset Management LLC now owns 1,084,634 shares of the company’s stock valued at $24,513,000 after purchasing an additional 364,391 shares in the last quarter. Finally, Pier Capital LLC bought a new stake in SI-BONE during the 4th quarter valued at $4,849,000.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma.